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Several states responded to federal funding limitations placed on human embryonic stem cell research and
the potential of the field by creating state stem cell funding programs, yet little is known about the impact of
these programs. Here we examine how state programs have affected publication trends in four states.INTRODUCTION
The isolation of human embryonic stem
cells (hESCs) in 1998 intensified discus-
sions about ethical issues associated
with stem cell research and inspired a
still-ongoing global policy debate over
the acceptability of and funding for
various types of stem cell research (Gott-
weis, 2010). In the U.S., three distinct fed-
eral funding policies—corresponding to
the Clinton, Bush, and Obama Adminis-
trations—have been adopted (Gottweis,
2010), and the policy environment has
been further complicated by uncertainty
associated with congressional action
and litigation (Levine, 2011).
Extensive policy action has also
occurred at the state level in the U.S.,
with states both supporting and restrict-
ing stem cell research and related areas
of scientific inquiry (Levine et al., 2013).
Six states—California, Connecticut, Illi-
nois, Maryland, New Jersey, and New
York—took the unusual step of dedicating
state funding to support basic and trans-
lational stem cell research (including
research using hESCs) (Karmali et al.,
2010). These state policies had several
goals encompassing the advancement
of science (including hESC research that
could not be conducted with federal
funding during the Bush Administration)
and economic development priorities.
Although stem cell funding programs in
Illinois and New Jersey have ceased
operations, funding programs of various
sizes—ranging up to California’s $3 billion
program—continue in the other fourstates (see Table 1 for details on these
programs and information on their size
relative to NIH funding in each state).
Despite the scale of these programs,
relatively little is known about their impact
on the field. One exception is a 2010
assessment that found that between
December 2005 and the end of 2009,
the programs collectively awarded nearly
750 grants totaling approximately $1.25
billion in state funding (Karmali et al.,
2010). This assessment found wide varia-
tion (ranging from 21% in New York and
New Jersey to 97% in Connecticut)
among the states in the extent to which
their grants focused on hESC research
and suggested that one key success of
the programs had been drawing new sci-
entists into the field of stem cell research
(Karmali et al., 2010).
As some of these state programs are
nearing the final years of their initial fund-
ing commitments, understanding their
effects on the scientific enterprise is an
increasingly important policy question.
Here, we contribute to this effort by exam-
ining publications in stem-cell-related
fields in the four states with sus-
tained stem cell funding programs and
comparing the share of hESC- and
induced pluripotent stem cell (iPSC)-
related publications with the share of
publications in other areas of biomed-
ical research (RNAi- and cancer-related
research), which were presumed to be
less affected by state policies. In addition,
we examine the funding sources acknowl-
edged in both hESC- and RNAi-related
publications to assess how state fund-Cell Stem Cell 16ing contributed to the differences we
observe. Our analysis builds on previous
efforts that have looked at the interna-
tional distribution of stem cell publications
generally (Guhr et al., 2006; Levine, 2004,
2008) and the publication performance of
the United States following the adoption
of the restrictive funding policy in the
Bush Administration more specifically
(Furman et al., 2012; Owen-Smith and
McCormick, 2006). (See Supplemental
Information for more details about our
analysis strategies.)
Publications Trends Vary by State
Wefirst looked at the share of U.S. hESC-,
iPSC-, RNAi-, and cancer-related publi-
cations with at least one author from Cal-
ifornia, Connecticut, Maryland, or New
York as well as the share of hESC-related
publications acknowledging funding from
each state (see Figure 1). We also group-
ed the publications based on when they
were published in relation to the various
policies that have been enacted. The dif-
ference between each state’s share of
hESC- and iPSC- related publications
and its share of cancer-related publica-
tions was calculated for three timeframes
(Table S1), which represent (1) the period
when hESCs were under investigation but
state policies had not yet been adopted
(early hESC: 1998–2004), (2) the period
during which most state stem cell funding
policies were adopted and awarded their
initial grants (adoption: 2005–2008), and
(3) the period when these programs were
up and running (implementation: 2009–
2013). Given time lags between funding, February 5, 2015 ª2015 Elsevier Inc. 115
Table 1. Overview of Four Major State Stem Cell Research Funding Programs
California Connecticut Maryland New York
First grants awarded 2006 2006 2007 2008
Initial funding/Time period $3B/10 years $100M/10 years N/A $600M/11 years
Approximate annual funding $300M $10M $14M $55M
NIH Funding (FY13)
hESC $36M (28.8%) $4.4M (3.5%) $2.4M (2.0%) $7.9M (6.4%)
SC $222M (20.3%) $21M (1.9%) $41M (3.8%) $108M (9.8%)
All $3.3B (14.8%) $445M (2.0%) $1.6B (7.1%) $1.9B (8.6%)
Notes: Approximate annual funding was calculated by dividing total commitment by time period of
commitment for California, Connecticut, and New York. Maryland’s approximate annual funding
was calculated by dividing its total funding through July 2014 by its years of operation. For compar-
ison, NIH funding received by each state for hESC, all stem cell (SC) and all extramural research is
shown for fiscal year 2013. The total dollar value of NIH funding was extracted from the NIH
RePORT system (http://report.nih.gov/), and the share of all NIH extramural funding in that category
was calculated from these data.
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fects would most likely be seen in the
publication record during this final period.
California’s share of publications in the
two comparison groups (RNAi- and can-
cer-related research) was quite consis-
tent. Between 15% and 18% of U.S. can-
cer-related publications had at least one
author from the state in each 2-year period
assessed between 1996 and 2013, and
following an initial period of growth, the
state’s share of RNAi-related publications
remained between 17% and 19% from
2002 through 2013. The state’s share of
hESC- and iPSC-related research differed
markedly from its share of these compar-
ison groups. Its share of hESC-related
research exceeded its share of the com-
parison groups as early as 2000 to 2001,
and this difference continued to grow in
future years, with the state’s share reach-
ing 45% in 2010 to 2011. California’s
share of iPSC-related research has been
high since shortly after the technology’s
discovery, with the state accounting for
44% of U.S. publications in 2008 to
2009. These differences are statistically
significant in both the adoption and imple-
mentation time periods for hESC-related
research and during the implementation
period for iPSC-related research (see
Table S1). After the California Institute for
Regenerative Medicine (CIRM) issued its
first grants in April 2006, the share of arti-
cles acknowledging California funding
increased rapidly from approximately
3% in 2006 to 2007 to more than 20% in
2010 to 2011 and 2012 to 2013. Overall,
California state funding was acknowl-
edged in nearly 19% of all hESC-related116 Cell Stem Cell 16, February 5, 2015 ª201articles in our data set published between
2006 and 2013, compared with 1.8% of
articles in a comparable set of RNAi-
related research (t test, p < 0.01). 45%
of the hESC-related articles published
between 2006 and 2013 in our data set
with at least one author from California
acknowledged funding from the state.
Similar trends were seen in Connecti-
cut. The state’s share of cancer-related
publications was relatively consistent,
ranging from 2% to 3% throughout the
time period studied, while the state’s
share of hESC-related research grew
from 0% in 2002 to 2003 to 6% in 2012
to 2013. Similar to California, Connecti-
cut’s share of iPSC-related research
publications exceeded its share of can-
cer-related research as early as 2008 to
2009, and in Connecticut’s case, this dif-
ference continued to grow through 2012
to 2013. These differences are statistically
significant in the implementation time pe-
riods for both hESC- and iPSC-related
research (see Table S1). Overall, Con-
necticut state funding was acknowledged
in 2.4% of all hESC-related articles pub-
lished between 2006 and 2013 in our
data set, compared with 0.2% of articles
in the comparable set of RNAi-related
research (t test, p < 0.01). 67% of the
hESC-related articles published between
2006 and 2013 in our data set with at least
one author from Connecticut acknowl-
edged funding from the state.
For Maryland and New York, in
contrast, the share of hESC- and iPSC-
related research in recent years was
similar to the share of the two compari-
son groups. Maryland’s share of hESC-5 Elsevier Inc.related research declined from a high of
22% in 2004 to 2005 to 10% in 2008 to
2009 before leveling off. State funding
from Maryland was acknowledged in
2.2% of the hESC-related articles pub-
lished between 2006 and 2013 in our
data set, with most of these state-sup-
ported articles published between 2010
and 2013. In New York, the share of
hESC-related research publications
grew from a low of 8% in 2008 to 2009
to 13% in 2012 to 2013 but, even
following this growth, remained similar to
the state’s share of publications in the
two comparison groups. Funding from
New York was also acknowledged in
2.2% of the hESC-related articles pub-
lished between 2006 and 2013 in our
data set, and most of these articles were
published between 2010 and 2013.
Policy Considerations
Our comparative analysis provides some
of the first evidence that the distribution
of stem-cell-related publications in the
United States differs from the distribution
of publications in fields not targeted by
specific state funding policies, and our
analysis of the funding sources acknowl-
edged in many of these articles strongly
suggests that state funding is responsible,
in part, for these differences. The share of
hESC- and iPSC-related publications pro-
duced in each of the four states examined
depends on a variety of considerations,
including the size, strengths, and interests
of the scientific community and the spe-
cifics of the policy itself (i.e., its timing, its
size, and its focus). In addition, it depends
on the competitive environment within the
UnitedStates, asover-performance inone
state must be balanced by under-perfor-
mance in others.
In both California and Connecticut,
state funding programs appear to have
contributed to over-performance in the
field. In California’s case, the state was
already a strong performer in hESC-
related research before its state funding
policy was adopted in 2004, and funding
began flowing in 2006. This may reflect a
generally supportive state environment
or a first-mover advantage, as Geron Cor-
poration, a key funder of early hESC
research, is based in the state. Following
passage of Proposition 71 in November
2004 and the creation of CIRM in
the ensuing years, the state’s share
of hESC-related research grew from
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Figure 1. Trends in State Publication Percentages for hESC-, iPSC-, RNAi-, and Cancer-Related Research
Note: Each panel shows the percentage of U.S. publications in the four fields with at least one author from the specified state (solid lines) and the percentage of
hESC-related research publications that acknowledged funding from the specified state (blue dashes). Vertical bars indicate the approximate time at which each
state stem cell program awarded its first grants. See also Table S1.
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more than 40%, and the state maintained
this position of strength in both hESC- and
iPSC-related research from 2008 through
the end of our data in 2013. Between 2010
and 2013, approximately 55% of hESC-
related articles published with at least
one California author acknowledged state
funding, suggesting that this funding pro-
gram played an important role as Califor-
nia maintained and built upon its early
leadership in the field. The Connecticut
case is even more suggestive of a policy
impact, as the state showed very little
hESC-related research activity through
2004 to 2005 and then showed steady
growth in publication share following
adoption of its funding policy in 2005,with approximately 67% of these articles
acknowledging state funding. These find-
ings align well with previous work (Karmali
et al., 2010) indicating that California and
Connecticut, at least in the early years of
their funding programs, focused more of
their grants on hESC research than did
other states. Given the close relationship
between hESC and iPSC research (Scott
et al., 2011), it is not surprising that,
although iPSC cells were not explicitly
prioritized by these state programs, these
states also produced a higher share of
iPSC-related research than they did in
the comparison fields.
In contrast to California and Con-
necticut, over-performance in pluripotent
stem cell research was not seen in Mary-Cell Stem Cell 16land and New York. Our analysis shows,
however, that state funding from each of
these states contributed to approximately
3% of the hESC-related publications in
our data set between 2010 and 2013.
This funding appears to have helped
these states maintain a share of hESC-
related research similar to their share in
the comparison fields, and given the
competitive environment with other states
investing heavily in stem cell research,
this may well be a successful policy
outcome.
This analysis illustrating the relative per-
formance of states in the production of
stem-cell-related research publications
provides a useful starting point for policy-
makersand,potentially, votersconsidering, February 5, 2015 ª2015 Elsevier Inc. 117
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aswell asothers interested in state science
and technology policy more generally. We
focused our analysis on hESC-related
research as this field was a key motivation
for some state stem cell funding programs
(Karmali et al., 2010), but futurework could
examine the effects of state stem cell
programs on the broader fields of stem
cell research and regenerative medicine.
In addition, while we analyzed hESC-and
iPSC-related research separately, these
fields are closely intertwined (Scott et al.,
2011) (see Supplemental Information
for discussion), and future work could
examine how state programs reacted to
the development of iPSCs and prioritized
their funding among these two related
but distinct forms of pluripotent stem
cell research. In addition, publications are
only one measure of the impact of state
science funding programs, and examining
other outcomes (e.g., patents awarded,
clinical trials initiated, etc.) is an important
topic for future investigation. Indeed,
more thorough efforts to evaluate these118 Cell Stem Cell 16, February 5, 2015 ª201state stem cell programs, ideally drawing
on the initial goals of the programs and a
wide range of relevant outcomes, would
be an important step to help assess their
impact on the field and the value of field-
specific state science funding programs
more generally.
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